Article
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.
Life science alliance - 1 Jun 2020
Ngan Hoi-Lam, Liu Yuchen, Fong Andrew Yuon, Poon Peony Hiu Yan, Yeung Chun Kit, Chan Sharon Suet Man, Lau Alexandria, Piao Wenying, Li Hui, Tse Jessie Sze Wing, Lo Kwok-Wai, Chan Sze Man, Su Yu-Xiong, Chan Jason Ying Kuen, Lau Chin Wang, Mills Gordon B, Grandis Jennifer Rubin, Lui Vivian Wai Yan
Abstract excerpt
MAPK pathway mutations affect one-fifth of head and neck squamous cell carcinoma (HNSCC). Unexpectedly, MAPK pathway aberrations are associated with remarkably long patient survival, even among patients with TP53 mutations (median ∼14 yr). We explored underlying outcome-favoring mechanisms with omics followed by preclinical models. Strikingly, multiple hotspot and non-hotspot MAPK mutations (A/BRAF, HRAS, MAPK1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.